The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
NLRP3 inflammasome activation drives tau pathology
Open accessAbstract
Alzheimer’s disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline1. The NLRP3 inflammasome assembles inside of microglia on activation, leading to increased cleavage and activity of caspase-1 and downstream interleukin-1β release2. Although the NLRP3 inflammasome has been shown to be essential for the development and progression of amyloid-beta pathology in mice3, the precise effect on tau pathology remains unknown. Here we show that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases. Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-containing brain homogenates induced tau pathology in an NLRP3-dependent manner. These data identify an important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies and support the amyloid-cascade hypothesis in Alzheimer’s disease, demonstrating that neurofibrillary tangles develop downstream of amyloid-beta-induced microglial activation. The authors show that NLRP3 inflammasome is activated in microglia of patients with fronto-temporal dementia and in a mouse model of tau pathology, and that the loss of NLRP3 inflammasome function decreases tau pathology and improves cognition in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The NLRP3-ASC inflammasome mechanisms contributing to increased beta-amyloids and tau are thought to be a combination of kinases and phosphatases involved in tau phosphorylation [96] through the production of IL-1 beta.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the CNS, inflammasome activation has been mainly linked to neuroinflammatory conditions. As example, it has an essential role in the progression of several neurological disorders like MS, AD, PPD, and NPS (132, 193–197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of hippocampal NLRP3 inflammasome-mediated pyroptosis is associated with neuronal damage, cognitive decline, and neuronal death (Hanslik & Ulland, 2020; Heneka et al., 2013; Ising et al., 2019; Venegas et al., 2017).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Ising et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, treatment of mouse primary hippocampal neurons with conditioned media from wild-type, but not Nlrp3−/− and Asc−/−, microglia primed with LPS resulted in elevated total and phosphorylated tau levels, suggesting that NLRP3 inflammasome activation in microglia can induce tau pathology in neurons.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, several cytokines, including IL-1β and IL-6, can directly induce tau phosphorylation in vitro, thus potentially contributing to the development of tau pathology.54”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [56]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Research by Ising et al. suggests that tau proteins can activate the NLRP3 inflammasome, which then promotes excessive tau phosphorylation and aggregation by affecting specific tau kinases and phosphatases.252”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [252]
The cited source says what the claim attributes to it.
In the citing paper
“In turn, the NLRP3 inflammasome is essential for the development and progression of Aβ pathology in mice29 and may drive tau pathology through Aβ-induced microglial activation30.”
From New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“A recent study shows that NLR family pyrin domain-containing protein 3 (NLRP3) inflammasome activation induces tau hyperphosphorylation and aggregation through modulating tau kinases and phosphatases [159].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [159]
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, microglia could also drive tau spreading and toxicity by promoting neuroinflammation, such as activating NACHT-, LRR- and pyrin (PYD)-domain-containing protein 3 (NLRP3) inflammasome155 or inducing NF-kB signaling.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [155]
The cited source says what the claim attributes to it.
In the citing paper
“Tau oligomers and monomers can also activate NLRP3 inflammasomes, further perpetuating microglial activation [162] and potential progression of tau pathology.”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [162]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment of wild-type primary microglia with recombinant wild-type tau and recombinant tau with a P301S mutation increased IL-1β secretion, an effect that was attenuated in Nlrp3−/− and Asc−/− microglia, suggesting that tau induces IL-1β secretion in a NLRP3-dependent manner [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Inhibiting or downregulating the NLRP3 inflammasome ameliorates AD neuropathology in animal models, which opens up a therapeutic avenue for modulators of NLRP3 activation in AD.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, treatment of mouse primary hippocampal neurons with conditioned media from wild-type, but not Nlrp3−/− and Asc−/−, microglia primed with LPS resulted in elevated total and phosphorylated tau levels, suggesting that NLRP3 inflammasome activation in microglia can induce tau pathology in neurons.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment of wild-type primary microglia with recombinant wild-type tau and recombinant tau with a P301S mutation increased IL-1β secretion, an effect that was attenuated in Nlrp3−/− and Asc−/− microglia, suggesting that tau induces IL-1β secretion in a NLRP3-dependent manner [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“The NLRP3 inflammasome has a bidirectional relationship with AD-related tau pathology as well.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that while some forms of tau can activate the NLRP3 inflammasome, inflammasome activation can exacerbate tau pathology by promoting elevated phosphorylation of tau [81, 82].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, treatment with brain homogenates from APP/PS1 mice induced tau hyperphosphorylation in a mouse model of tau aggregation pathology (Tau22) but not in Tau22/Nlrp3−/− and Tau22/Asc−/− mice, indicating the NLRP3 inflammasome as a mediator of Aβ-induced tau pathology [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, treatment with brain homogenates from APP/PS1 mice induced tau hyperphosphorylation in a mouse model of tau aggregation pathology (Tau22) but not in Tau22/Nlrp3−/− and Tau22/Asc−/− mice, indicating the NLRP3 inflammasome as a mediator of Aβ-induced tau pathology [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that while some forms of tau can activate the NLRP3 inflammasome, inflammasome activation can exacerbate tau pathology by promoting elevated phosphorylation of tau [81, 82].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“In Tau22 mice, ablation of Nlrp3 or Asc reduced levels of hyperphosphorylated tau and tau aggregates and rescued tau-induced spatial memory deficits [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
In the citing paper
“Studies have demonstrated important roles of the NLRP3 inflammasome in aging and age-related diseases, such as atherosclerosis metabolic syndrome, type 2 diabetes, and Alzheimer’s disease (81–83).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“For example, in AD and frontotemporal dementia, neuroinflammation and microglia activation potentiate the spreading of pathological tau neurofibrillary tangles (83, 175).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“In AD, this relationship may be mediated by NLRP3 inflammasome activation in microglia, a process that activates tau kinases (e.g., GSK-3β and CaMKII-α) and results in tau hyperphosphorylation (83).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“The knockout of ASC or NLRP3 ameliorates AD‐like brain pathology in animal models. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“The activation of the NLRP3 inflammasome drives tau pathology. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“Inflammaging can drive tau pathology and neurodegeneration in AD by impairing the clearance of Aβ peptides, altering BBB integrity, and affecting the synaptic functions. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“In general, patients affected by tauopathies showed elevated levels of cleaved caspase-1 and ASC and mature IL-1β in the cortex (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Injecting brain homogenates from APP/PS1 or wild-type mice into the hippocampus of Tau22 mice, induced tau hyperphosphorylation in the hippocampus of Tau22 wild-type but not Tau22/Pycard−/− or Tau22/Nlrp3−/− deficient mice”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“suggesting that NLRP3 activation is upstream the Aβ-tau cascade and tau pathology (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Consistent with this, Tau22 mice lacking ASC or NLRP3 expression had lower levels of aggregated and hyperphosphorylated tau in the hippocampus, and their typical spatial memory deficits were rescued (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Also, Tau22 mice, another model of AD and other tauopathies, had increased levels of cleaved caspase-1 and ASC in their brain at the age of 11 months compared to their 3-month-old counterparts.”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Further, activated microglia promote tau phosphorylation and aggregation by activation of the NLRP3 (nucleotide binding oligomerisation domain (NOD)-, leucine-rich repeat (LRR)- and pyrin domain-containing protein 3) inflammasome in response to amyloid-β [22,23].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“Further, there is evidence tauopathy is driven by NLRP3 inflammasome activation in microglia in response to amyloid-β [23].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“ROS from NOX4 also contribute to activation of the NLRP3 inflammasome, a driver of both amyloid-β [156] and tau [23] pathology.”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“Growing evidence indicates that Aβ accumulation stimulates tau phosphorylation and fibrillary tangle formation, leading to the process of neurodegeneration.112–114”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [112]
In the citing paper
“In particular, microglial NLRP3 has been shown to be a major driver of amyloid beta and tau toxicity in AD, suggesting its activation has important implications for disease progression (Halle et al, 2008; Venegas et al, 2017; Ising et al, 2019).”
From Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease (2022) · cites this paper as Ising et al, 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw937 · Cited by 6,980
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898
Self-citationThe NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Self-citationDepletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T., Özören, N., Body–Malapel, M., Amer, A. O., Park, J., Franchi, L., Whitfield, J. R., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,149
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease
Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R., Tejera, D., Vieira-Saecker, A., Schwartz, S., Santarelli, F., Kummer, M. P., et al. (2017) · Nature · doi:10.1038/nature25158 · Cited by 983
Self-citationInflammasome signalling in brain function and neurodegenerative disease
Heneka, M. T., McManus, R. M., & Latz, E. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0055-7 · Cited by 836
Self-citationCanonical Nlrp3 Inflammasome Links Systemic Low-Grade Inflammation to Functional Decline in Aging
Youm, Y.-H., Grant, R. W., McCabe, L. R., Albarado, D. C., Nguyen, K. Y., Ravussin, A., Pistell, P., Newman, S., Carter, R., Laque, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.09.010 · Cited by 674
Cited by
Sorted by citations
Items 401–500 of 1,003
Fenamates as Potential Therapeutics for Neurodegenerative Disorders
Hill, J., & Zawia, N. H. (2021) · Cells · doi:10.3390/cells10030702 · Cited by 37
Ma, C., Wu, Y., Song, L., Yin, L., Yin, J.-J., Wang, Q., Yu, J., & Xiao, B. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355747 · Cited by 37
The Potential of NLRP3 Inflammasome as a Therapeutic Target in Neurological Diseases
He, W., Hu, Z., Zhong, Y., Wu, C., & Li, J. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03229-7 · Cited by 38
Zhang, S.-S., Gao, Z., Feng, L., & Li, M. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s483412 · Cited by 39
Self-citationModulating Neuroinflammation as a Prospective Therapeutic Target in Alzheimer’s Disease
Lee, E., & Chang, Y. (2025) · Cells · doi:10.3390/cells14030168 · Cited by 39
Donison, N. S., Palik, J., Volkening, K., & Strong, M. J. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00842-z · Cited by 42
The expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets
Weber, A. N. R., McManus, R. M., Hornung, V., Geyer, M., Kuemmerle-Deschner, J. B., & Latz, E. (2025) · Nature Immunology · doi:10.1038/s41590-025-02230-7 · Cited by 46
Self-citationBarnett, D., Zimmer, T. S., Booraem, C., Palaguachi, F., Meadows, S. M., Xiao, H., Wong, M. Y., Luo, W., Gan, L., Chouchani, E. T., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01390-y · Cited by 41
Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer’s disease
Ferrari‐Souza, J. P., Povala, G., Rahmouni, N., Bellaver, B., Ferreira, P. C. L., Bastiani, M. A. D., Leffa, D. T., Lussier, F. Z., Aguzzoli, C. S., Brum, W. S., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02103-0 · Cited by 46
Hyperexcitability and seizures in the THY-Tau22 mouse model of tauopathy
Gómez‐Murcia, V., Sandau, U. S., Ferry, B., Parrot, S., Laurent, C., Basquin, M., Buée, L., Boison, D., & Blum, D. L. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.06.004 · Cited by 36
Self-citationThe Role of Insulin Signaling in Hippocampal-Related Diseases: A Focus on Alzheimer’s Disease
Liu, Q., Wang, Z., Cao, J., Dong, Y., & Chen, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214417 · Cited by 42
Yan, Z., Qi, Z., Yang, X., Ji, N., Wang, Y., Shi, Q. W., Li, M., Zhang, J., & Zhu, Y. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30285 · Cited by 35
Dysfunctional microglia and tau pathology in Alzheimer’s disease
Ayyubova, G. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0087 · Cited by 36
CX3CL1 Pathway as a Molecular Target for Treatment Strategies in Alzheimer’s Disease
Bivona, G., Iemmolo, M., & Ghersi, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098230 · Cited by 35
Immune modulation to treat Alzheimer’s disease
Duggan, M. R., Morgan, D., Price, B. R., Rajbanshi, B., Martín‐Peña, A., Tansey, M. G., & Walker, K. A. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00828-x · Cited by 44
A role for microglia in mediating the microbiota–gut–brain axis
Keane, L., Clarke, G. A., & Cryan, J. F. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01188-9 · Cited by 43
Španić, E., Horvat, L. L., Ilić, K., Hof, P. R., & Šimić, G. (2022) · Cells · doi:10.3390/cells11142223 · Cited by 35
Maran, J. J., Adesina, M. M., Green, C. R., Kwakowsky, A., & Mugisho, O. O. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101954 · Cited by 38
Characterizing microglial senescence: Tau as a key player
Karabag, D., Scheiblich, H., Griep, A., Santarelli, F., Schwartz, S., Heneka, M. T., & Ising, C. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15866 · Cited by 35
Self-citationShakaib, B., Zohra, T., Ikram, A., Shakaib, M. B., Ali, A. A. A., Bashir, A., Salman, M., Khan, M. A., & Ansari, J. A. (2021) · Virology Journal · doi:10.1186/s12985-021-01578-0 · Cited by 34
Wang, G., Yin, W., Shin, H., Tian, Q., Lü, W., & Hou, X. S. (2021) · Nature Aging · doi:10.1038/s43587-021-00130-7 · Cited by 40
Infection and inflammation: New perspectives on Alzheimer's disease
Whitson, H. E., Colton, C. A., Khoury, J. B. E., Gate, D., Goate, A., Heneka, M. T., Kaddurah‐Daouk, R., Klein, R. S., Shinohara, M. L., Sisodia, S. S., et al. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100462 · Cited by 34
Self-citationHan, S., He, Z., Hu, X., Li, X., Zheng, K., Huang, Y., Xiao, P., Xie, Q., Ni, J., & Liu, Q. (2023) · Antioxidants · doi:10.3390/antiox12030722 · Cited by 34
Ungvari, A., Gulej, R., Csík, B., Mukli, P., Negri, S., Tarantini, S., Yabluchanskiy, A., Benyó, Z., Csiszár, A., & Ungvari, Z. I. (2023) · Nutrients · doi:10.3390/nu15214662 · Cited by 34
Enhancing mitophagy as a therapeutic approach for neurodegenerative diseases
Aman, Y., Ryan, B. J., Torsetnes, S. B., Knapskog, A., Watne, L. O., McEwan, W. A., & Fang, E. F. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.02.008 · Cited by 36
Hull, C. E., Dekeryte, R., Buchanan, H. M., Kamli-Salino, S., Robertson, A. A. B., Delibegović, M., & Platt, B. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108305 · Cited by 34
Jiang, C., Zhang, Y., Tang, X., Jing, C., Qiu, S., Li, B., & Li, Y. (2021) · Neuroreport · doi:10.1097/wnr.0000000000001661 · Cited by 34
Gessi, S., Poloni, T. E., Negro, G., Varani, K., Pasquini, S., Vincenzi, F., Borea, P. A., & Merighi, S. (2021) · Cells · doi:10.3390/cells10092344 · Cited by 36
Inflammasome activation in neurodegenerative diseases
Ravichandran, K. A., & Heneka, M. T. (2021) · Essays in Biochemistry · doi:10.1042/ebc20210021 · Cited by 37
Self-citationYang, T., Zhang, L., Shang, Y., Zhu, Z., Jin, S., Guo, Z., & Wang, X. (2022) · Chemical Science · doi:10.1039/d1sc06071f · Cited by 34
Du, H., Li, C., Gao, R., Cen, X.-Q., & Li, P. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.915969 · Cited by 34
Rubinski, A., Franzmeier, N., Dewenter, A., Luan, Y., Smith, R. A., Strandberg, O. T., Ossenkoppele, R., Dichgans, M., Hansson, O., Ewers, M., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01074-9 · Cited by 41
Viney, T. J., Sárkány, B., Ozdemir, A. T., Hartwich, K., Schweimer, J. V., Bannerman, D. M., & Somogyi, P. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111646 · Cited by 37
Guerville, F., Vialemaringe, M., Cognet, C., Duffau, P., Lazaro, E., Cazanave, C., Bonnet, F., Leleux, O., Rossignol, R., Pinson, B., et al. (2023) · AIDS · doi:10.1097/qad.0000000000003546 · Cited by 36
Nanomedicines for Alzheimer's disease: Therapies based on pathological mechanisms
Cheng, G., Xie, A., Yan, Z., Zhu, X., Song, Y., & Chen, T. (2023) · Brain‐X · doi:10.1002/brx2.27 · Cited by 35
Pampuščenko, K., Morkūnienė, R., Krasauskas, L., Smirnovas, V., Brown, G. C., & Borutaitė, V. (2023) · Scientific Reports · doi:10.1038/s41598-023-37887-3 · Cited by 31
Misiura, M. B., Butts, B., Hammerschlag, B. L., Munkombwe, C., Bird, A., Fyffe, M., Hemphill, A., Dotson, V. M., & Wharton, W. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01408-x · Cited by 35
Ng, R. C.-L., Jian, M., Ma, O. K.-F., Xiang, A. W., Bunting, M., Kwan, J., Wong, C. W.-K., Yick, L.-W., Chung, S. K., Lam, K. S. L., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03066-y · Cited by 35
Severini, C., Barbato, C., Certo, M. G. D., Gabanella, F., Petrella, C., Stadio, A. D., VINCENTIIS, M. D., Polimeni, A., Ralli, M., & Greco, A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200621204546 · Cited by 34
Mattson, M. P. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.01.006 · Cited by 33
Heinz, R., & Schneider, U. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012618 · Cited by 33
Vogrinc, D., Kramberger, M. G., Emeršič, A., Čučnik, S., Goričar, K., & Dolžan, V. (2023) · Antioxidants · doi:10.3390/antiox12020316 · Cited by 38
Liu, X., Cheng, Z.-Y., Li, Y.-F., Liu, C., Wang, C., Gong, X., & He, L. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175443 · Cited by 32
Boraschi, D., Italiani, P., Migliorini, P., & Bossù, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1128190 · Cited by 38
Zhang, Y., Miao, Y., Xiong, X., Tan, J., Han, Z., Chen, F., Lei, P., & Zhang, Q. (2023) · Biology Direct · doi:10.1186/s13062-023-00387-5 · Cited by 34
Chu, F.-X., Wang, X., Li, B., Xu, L., & Di, B. (2024) · Inflammation Research · doi:10.1007/s00011-023-01831-y · Cited by 33
The menace within: bacterial amyloids as a trigger for autoimmune and neurodegenerative diseases
Elkins, M., Jain, N., & Tükel, Ç. (2024) · Current Opinion in Microbiology · doi:10.1016/j.mib.2024.102473 · Cited by 34
Galectins in the brain: advances in neuroinflammation, neuroprotection and therapeutic opportunities
Barake, F., Soza, A., & González, A. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000812 · Cited by 33
Eckenweber, F., Medina-Luque, J., Blume, T., Sacher, C., Biechele, G., Wind, K., Deussing, M., Briel, N., Lindner, S., Boening, G., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01883-5 · Cited by 32
Söderbom, G., & Zeng, B. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.023 · Cited by 32
Kinra, M., Joseph, A., Nampoothiri, M., Arora, D. S., & Mudgal, J. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105637 · Cited by 33
Neutrophils Facilitate Prolonged Inflammasome Response in the DAMP-Rich Inflammatory Milieu
Son, S., Yoon, S.-H., Chae, B. J., Hwang, I., Shim, D.-W., Choe, Y. H., Hyun, Y., & Yu, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.746032 · Cited by 34
Nampoothiri, M., Gurram, P. C., Manandhar, S., Satarker, S., Mudgal, J., & Arora, D. S. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220413090541 · Cited by 33
Ossola, B., Rifat, A., Rowland, A., Hunter, H., Drinkall, S., Bender, C., Hamlischer, M., Teall, M. R., Burley, R., Barker, D. F., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109330 · Cited by 30
Research progress of NLRP3 inflammasome and its inhibitors with aging diseases
Yuan, Z., Yu, D., Gou, T., Tang, G., Guo, C., & Shi, J. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175931 · Cited by 33
Lin, W., Zhao, L., Liang, G., Zhou, R., Zheng, X., Tao, R., Huo, Q., Su, C.-F., Li, M., Xu, N., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02698-w · Cited by 32
Roth‐Walter, F., Adcock, I. M., Benito‐Villalvilla, C., Bianchini, R., Bjermer, L. H., Caramori, G., Cari, L., Chung, K. F., Diamant, Z., Eguíluz‐Gracia, I., et al. (2023) · Allergy · doi:10.1111/all.15977 · Cited by 31
The Role of Chronic Infection in Alzheimer’s Disease: Instigators, Co-conspirators, or Bystanders?
Butler, L., & Walker, K. A. (2021) · Current Clinical Microbiology Reports · doi:10.1007/s40588-021-00168-6 · Cited by 30
Li, J., Wang, J., Wang, Y., Luo, Z., Zheng, C., Yu, G., Wu, S., Zheng, F., & Li, H. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112725 · Cited by 31
Wang, X., Gao, F., Xu, W., Cao, Y., Wang, J., & Zhu, G. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/1020614 · Cited by 32
Hausrat, T. J., Janiesch, P. C., Breiden, P., Lutz, D., Hoffmeister‐Ullerich, S., Hermans‐Borgmeyer, I., Failla, A. V., & Kneussel, M. (2022) · Nature Communications · doi:10.1038/s41467-022-31776-5 · Cited by 29
The Significance of NLRP Inflammasome in Neuropsychiatric Disorders
Shen, Y., Qian, L., Luo, H., Li, X., Ruan, Y., Fan, R., Si, Z., Chen, Y.-P., Li, L., & Liu, Y. (2022) · Brain Sciences · doi:10.3390/brainsci12081057 · Cited by 32
Fertan, E., Böken, D., Murray, A., Danial, J. S. H., Lam, J. Y. L., Wu, Y., Goh, P. A., Alić, I., Cheetham, M. R., Lobanova, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02333-3 · Cited by 31
Yang, J., Shi, X., Wang, Y., Ma, M., Liu, H., Wang, J., & Xu, Z. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230593 · Cited by 33
Liang, N., Nho, K. T., Newman, J. W. I., Arnold, M., Huynh, K., Meikle, P. J., Borkowski, K., Kaddurah‐Daouk, R., Kueider‐Paisley, A., Doraiswamy, P. M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-67177-5 · Cited by 37
Jiang, Y., Wang, Z., Wang, W., Liu, Y., Meng, Y., Wang, Y., Fan, M., & Cai, C. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119065 · Cited by 30
Microglia programmed cell death in neurodegenerative diseases and CNS injury
Cai, L., Fan, Q., Pang, R., Chen, C., Zhang, Y., Xie, H., Huang, J., Wang, Y., Li, P., Huang, D., et al. (2024) · APOPTOSIS · doi:10.1007/s10495-024-02041-5 · Cited by 32
Zhou, F., Lian, W., Yuan, X., Wang, Z., Xia, C., Yu, Y., Wang, W., Tong, Z., Cheng, Y., Xu, J., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01695-w · Cited by 32
Early microglial and astrocyte reactivity in preclinical Alzheimer's disease
Fernández‐Matarrubia, M., Barrero, A. V., Renuncio‐García, M., Aguilella, M., Lage, C., López‐García, S., Ocejo-Vinyals, J. G., Martínez‐Dubarbie, F., Molfetta, G. D., Pozueta‐Cantudo, A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70502 · Cited by 37
Glial Cell Dysfunction in C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Ghasemi, M., Keyhanian, K., & Douthwright, C. L. (2021) · Cells · doi:10.3390/cells10020249 · Cited by 35
The role of P2X7R in neuroinflammation and implications in Alzheimer's disease
Chen, Y.-H., Lin, R.-R., & Tao, Q. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119187 · Cited by 35
The role of the inflammasomes in the pathogenesis of uveitis
Xu, Q., Zhang, J., Qin, T., Bao, J., Dong, H., Zhou, X., Hou, S., & Mao, L. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108618 · Cited by 30
NLRP3 Inflammasome Mediates Neurodegeneration in Rats with Chronic Neuropathic Pain
Ren, C., Chen, M., Mu, G., Peng, S., Liu, X., & Ou, C. (2021) · Shock · doi:10.1097/shk.0000000000001832 · Cited by 30
Microglia and its Genetics in Alzheimer's Disease
Liang, X., Wu, H., Colt, M., Guo, X., Pluimer, B. R., Zeng, J., Dong, S., & Zhao, Z. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211105140732 · Cited by 32
Targeting Necroptosis as a Promising Therapy for Alzheimer’s Disease
Zhao, W., Liu, Y., Xu, L., He, Y., Cai, Z., Yu, J., Zhang, W., Xing, C., Zhuang, C., & Qu, Z. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00172 · Cited by 31
Based on molecular structures: Amyloid-β generation, clearance, toxicity and therapeutic strategies
Yang, H., Li, J., Li, X., Ma, L., Hou, M., Zhou, H., & Zhou, R. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.927530 · Cited by 33
Li, J., Li, L., He, J., Xu, J., & Bao, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1072003 · Cited by 31
Chen, Y., Yang, C. H., Zou, M., Wang, D., Sheng, R., Zhan, M., Chen, Q., Yang, W., Liu, X., & Xu, S. (2023) · Phytotherapy Research · doi:10.1002/ptr.7767 · Cited by 29
Park, J.-H., Hwang, J.-W., Lee, H., Jang, G. M., Jeong, Y. J., Cho, J., Seo, J., & Hoe, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1150940 · Cited by 29
Ma, Q., & Lim, C. S. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031023-125300 · Cited by 36
Bio–Nano Toolbox for Precision Alzheimer's Disease Gene Therapy
Liu, Y., Xia, X., Zheng, M., & Shi, B. (2024) · Advanced Materials · doi:10.1002/adma.202314354 · Cited by 31
Aβ1-42 promotes microglial activation and apoptosis in the progression of AD by binding to TLR4
Dou, R.-X., Zhang, Y., Hu, X., Gao, F.-L., Zhang, L., Liang, Y.-H., Zhang, Y.-Y., Yao, Y.-P., Li, Y., Zhang, Y., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103428 · Cited by 32
CLEC16A in astrocytes promotes mitophagy and limits pathology in a multiple sclerosis mouse model
Kadowaki, A., Wheeler, M. A., Li, Z., Andersen, B. M., Lee, H., Illouz, T., Lee, J.-H., Ndayisaba, A., Zandee, S., Basu, H., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-01875-9 · Cited by 30
Microglia-driven inflammation induces progressive tauopathies and synucleinopathies
Lee, S. H., Bae, E.-J., Park, S. J., & Lee, S. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01450-z · Cited by 31
Shen, X., Li, H., Zhang, B., Li, Y., & Zhu, Z. (2025) · Cells · doi:10.3390/cells14191506 · Cited by 33
Carnosine ameliorates age-related dementia via improving mitochondrial dysfunction in SAMP8 mice
Dai, Z., Lu, X., Zhu, W., Liu, X.-Q., Li, B., Song, L., Liu, H.-F., Cai, W.-W., Deng, Y.-X., Xu, T., et al. (2020) · Food & Function · doi:10.1039/c9fo02453k · Cited by 31
Self-citationPotential Role of Extracellular CIRP in Alcohol-Induced Alzheimer’s Disease
Sharma, A., Brenner, M., & Wang, P. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02075-1 · Cited by 28
Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?
Merighi, S., Poloni, T. E., Terrazzan, A., Moretti, E., Gessi, S., & Ferrari, D. (2021) · Cells · doi:10.3390/cells10051267 · Cited by 30
Takata, K., Kimura, H., Yanagisawa, D., Harada, K., Nishimura, K., Kitamura, Y., Shimohama, S., & Tooyama, I. (2022) · Molecules · doi:10.3390/molecules27092780 · Cited by 29
Yu, D., Zarate, N., White, A., Coates, D., Tsai, W., Nanclares, C., Cuccu, F., Yue, J. S., Brown, T. G., Mansky, R. H., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01379-8 · Cited by 30
Harrison, D., Bock, M. G., Doedens, J. R., Gabel, C. A., Holloway, M. K., Lewis, A., Scanlon, J., Sharpe, A., Simpson, I. D., Smolak, P. J., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00242 · Cited by 29
Wątroba, M., & Szukiewicz, D. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.962769 · Cited by 29
Risen, S. J., Boland, S. W., Sharma, S., Weisman, G. M., Shirley, P. M., Latham, A. S., Hay, A. J. D., Gilberto, V. S., Hines, A. D., Brindley, S. M., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00846 · Cited by 27
Traumatic brain injury and the pathways to cerebral tau accumulation
Flavin, W. P., Hosseini, H. C., Ruberti, J. W., Kavehpour, H. P., Giza, C. C., & Prins, M. L. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1239653 · Cited by 33
Yan, H., Wang, W., Cui, T., Shao, Y., Li, M., Fang, L., & Feng, L. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s455881 · Cited by 32
The complex effects of miR-146a in the pathogenesis of Alzheimer’s disease
Long, Y., Liu, J., Wang, Y., Guo, H.-D., & Cui, G.-H. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01566 · Cited by 34
Microglial dysfunction in Alzheimer's disease: Mechanisms, emerging therapies, and future directions
Azmal, M., Paul, J. K., Prima, F. S., Haque, A. N. M. S. N. B., Meem, M., & Ghosh, A. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115374 · Cited by 30
Dunlap, C. F., Colachis, S. C., Meyers, E., Bockbrader, M. A., & Friedenberg, D. A. (2020) · Frontiers in Neurorobotics · doi:10.3389/fnbot.2020.558987 · Cited by 30
Discovery and characterization of small-molecule inhibitors of NLRP3 and NLRC4 inflammasomes
Sebastian-Valverde, M., Wu, H. D., Rahim, M. A., Sánchez, R., Kumar, K., Vita, R. J. D., & Pasinetti, G. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100597 · Cited by 30
Vautheny, A., Duwat, C., Aurégan, G., Joséphine, C., Hérard, A.-S., Jan, C., Mitja, J., Gipchtein, P., Gaillard, M.-C., Buée, L., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105398 · Cited by 28
Self-citation
Metadata
- Authors
- Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S. V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R. M., Tejera, D., Griep, A., Santarelli, F., Brosseron, F., Opitz, S., Stunden, J., Merten, M., Kayed, R., Golenbock, D. T., Blum, D., Latz, E., Buée, L., & Heneka, M. T.
- Affiliations
- University Hospital Bonn (DE)
- German Center for Neurodegenerative Diseases (DE)
- The University of Texas Medical Branch at Galveston (US)
- University of Massachusetts Chan Medical School (US)
- Inserm (FR)
- Corresponding author
- Heneka, Michael T.
- ORCID
- Venue
- Nature
- Published
- 2019-11-20
- Volume
- 575
- Issue
- 7784
- Pages
- 669-673
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7324015
- OpenAlex
- W2990312754
- Semantic Scholar
- 6a9d745a33a2d013c621f57586d9d719671530a7
- Cited by
- 1,487
- References
- 28
- Citations by year
- 2026: 189 · 2025: 226 · 2024: 255 · 2023: 226 · 2022: 248 · 2021: 193 · 2020: 143 · 2019: 3
- FWCI
- 101.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by-nc-nd)
- DZNE Pub (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (R01 AG059752-02)
- Agence Nationale de la Recherche (ANR-11-LABX-0009)
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- National Institutes of Health
- National Institute on Aging (R01AG059752, R01AG054025)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- NLRP3 inflammasome, tau hyperphosphorylation, tau aggregation, neurofibrillary tangles, Alzheimer's disease, amyloid-beta, microglia, amyloid hypothesis, frontotemporal dementia, neuroinflammation, caspase-1, IL-1β
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Gene Expression Regulation, Humans, Mice, Inbred C57BL, Phosphorylation, tau Proteins, Microglia, Cyclin-Dependent Kinase 5, Mice, Inflammasomes, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
